Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sleep Disorders Discussed: Fujisawa, Sanofi-Synthelabo Seminar
April 8, 2002
- Korosho Announces New Research Projects for FY2002
April 8, 2002
- Our Growth Not Enough for Survival: Mr Yokotsuka of Sumitomo
April 1, 2002
- PMS Measures to Be Strengthened in PAL Amendment
April 1, 2002
- Kansai Bio Conference in Kobe Focuses on Regenerative Medicine
April 1, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 1, 2002
- Ono's Elaspol Recommended for Approval by CDFS Department
April 1, 2002
- Makers Are Not Supplying Sufficient Information to Pharmacies: Survey
April 1, 2002
- Meiji Licenses Carbapenem from Wyeth Lederle
April 1, 2002
- Korosho to List All Generics on Website
April 1, 2002
- AJD Develops New Medical Bill Processing System
April 1, 2002
- Suntory, Daiichi to Codevelop Memantine for Alzheimer's Dementia
April 1, 2002
- Hepatitis C Detected in Majority of Users of Non-heated Blood Products
April 1, 2002
- Kraft Opens New Store with Independent Dispensing, Drugstore Divisions
April 1, 2002
- Daiichi Subscribes to Gene Logic's BioExpress
April 1, 2002
- Drugs with Limited Administration Period Announced
April 1, 2002
- OTC NEWS IN BRIEF
April 1, 2002
- Kyorin to Transfer Marketing of Pekiron to Galderma
April 1, 2002
- Korosho to Start Evaluating Its Policy Achievements in April
April 1, 2002
- WORLD NEWS IN BRIEF
April 1, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…